These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 22734440)

  • 21. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
    Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
    Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
    Rosenstock J; Balas B; Charbonnel B; Bolli GB; Boldrin M; Ratner R; Balena R;
    Diabetes Care; 2013 Mar; 36(3):498-504. PubMed ID: 23139373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.
    Pencek R; Blickensderfer A; Li Y; Brunell SC; Chen S
    Int J Clin Pract; 2012 Nov; 66(11):1021-32. PubMed ID: 22925173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of exenatide as a diabetes therapeutic.
    Bhavsar S; Mudaliar S; Cherrington A
    Curr Diabetes Rev; 2013 Mar; 9(2):161-93. PubMed ID: 23256660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
    Buse JB; Nauck M; Forst T; Sheu WH; Shenouda SK; Heilmann CR; Hoogwerf BJ; Gao A; Boardman MK; Fineman M; Porter L; Schernthaner G
    Lancet; 2013 Jan; 381(9861):117-24. PubMed ID: 23141817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM; Li Y; Porter TK; Weaver C; Han J
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
    Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
    Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
    Scheen AJ
    Rev Med Liege; 2014 Apr; 69(4):214-9. PubMed ID: 24923102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ; Moniri NH; Smiley DD
    Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
    Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G
    Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
    Tzefos M; Olin JL
    Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
    Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
    Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.